Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMKX003948 in Renal Cell Carcinoma
NCT06321250Phase 1Recruiting
- Sponsor
- Jemincare
- Start
- Mar 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of JMKX003948 in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by Jemincare. Primary endpoints: Dose Limiting Toxicities up to 2 months, Adverse Events and Serious Adverse Events up to 2 years and 1 more. Started Mar 2024; status: recruiting.
02
Drugs
JMKX003948
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06321250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06321250.